天康生物
(002100)
| 流通市值：84.78亿 | | | 总市值：84.78亿 |
| 流通股本：13.65亿 | | | 总股本：13.65亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,254,919,831.21 | 3,101,780,923.63 | 3,650,405,232.45 | 2,862,751,583.55 |
| 衍生金融资产 | 9,989,820 | 30,238,770 | 50,239,720 | 10,928,020 |
| 应收票据及应收账款 | 630,677,108.44 | 533,994,657.54 | 749,252,664.5 | 613,496,831.43 |
| 其中：应收票据 | 57,943,891.45 | 64,567,353.81 | 73,897,110.28 | 13,472,571.03 |
| 应收账款 | 572,733,216.99 | 469,427,303.73 | 675,355,554.22 | 600,024,260.4 |
| 应收款项融资 | 3,959,749.2 | 84,000 | 11,281,090.5 | 2,293,230.66 |
| 预付款项 | 659,929,966.93 | 836,719,408.76 | 862,495,429 | 316,219,930.34 |
| 其他应收款合计 | 301,209,284.18 | 266,561,111.07 | 371,108,008.04 | 283,766,948.98 |
| 存货 | 4,892,343,648.07 | 4,593,611,881.23 | 2,995,707,795.88 | 4,324,528,777.21 |
| 其他流动资产 | 475,721,585 | 479,237,493.62 | 414,372,439.29 | 483,235,341.59 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 10,244,239,958.97 | 9,847,752,197.03 | 9,115,407,832.64 | 8,897,743,168.88 |
| 非流动资产: | | | | |
| 长期股权投资 | 25,703,274.3 | 33,289,026.29 | 33,557,734.7 | 33,829,509.69 |
| 固定资产 | 5,768,284,179.51 | 5,889,854,376.07 | 5,810,834,455.61 | 5,275,821,292.65 |
| 在建工程 | 237,709,810.84 | 233,094,837.82 | 361,581,003.77 | 842,659,427.57 |
| 生产性生物资产 | 277,446,217.62 | 272,429,943.75 | 280,753,800.16 | 292,697,549.84 |
| 使用权资产 | 536,759,710.1 | 579,262,294.03 | 608,222,219.8 | 631,357,615.02 |
| 无形资产 | 372,882,709.31 | 377,167,563.83 | 389,627,564.51 | 385,712,786.27 |
| 开发支出 | 7,184,935.48 | 7,150,000 | 3,160,945.29 | 750,000 |
| 商誉 | 165,816,290.24 | 165,816,290.24 | 178,477,452.07 | 178,477,452.07 |
| 长期待摊费用 | 23,609,481.62 | 19,332,855.24 | 18,863,067.67 | 20,842,652.13 |
| 递延所得税资产 | 108,924,417.34 | 99,138,552.82 | 92,261,994.7 | 74,658,527.12 |
| 其他非流动资产 | 29,974,334 | 38,224,334 | 29,230,334 | 17,969,934 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 7,554,295,360.36 | 7,714,760,074.09 | 7,806,570,572.28 | 7,754,776,746.36 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 17,798,535,319.33 | 17,562,512,271.12 | 16,921,978,404.92 | 16,652,519,915.24 |
| 流动负债: | | | | |
| 短期借款 | 3,122,728,564.33 | 3,233,318,333.91 | 2,537,021,478.74 | 2,696,058,721.89 |
| 衍生金融负债 | 1,254,370 | 256,000 | - | - |
| 应付票据及应付账款 | 487,277,210.89 | 611,864,737.84 | 612,285,051.23 | 580,497,806.69 |
| 其中：应付票据 | 3,862,500 | 10,591,650 | 14,849,491.93 | 23,788,021.93 |
| 应付账款 | 483,414,710.89 | 601,273,087.84 | 597,435,559.3 | 556,709,784.76 |
| 预收款项 | 171,842.84 | 357,077.12 | - | - |
| 合同负债 | 892,793,544.26 | 665,659,287.76 | 735,335,510.43 | 498,671,966.26 |
| 应付职工薪酬 | 249,511,721.91 | 254,913,769.64 | 233,701,919.22 | 220,155,750.6 |
| 应交税费 | 27,961,270.9 | 24,781,256.99 | 33,920,966.77 | 9,101,896.72 |
| 其他应付款合计 | 646,984,388.16 | 698,553,772.85 | 769,957,597.07 | 693,751,266.93 |
| 一年内到期的非流动负债 | 1,160,223,329.1 | 865,902,294.41 | 1,090,031,838.11 | 1,602,065,146.92 |
| 其他流动负债 | 111,713,085.82 | 139,259,448.37 | 150,544,894.23 | 64,233,941.19 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 6,700,619,328.21 | 6,494,865,978.89 | 6,162,799,255.8 | 6,364,536,497.2 |
| 非流动负债: | | | | |
| 长期借款 | 1,984,174,931.12 | 2,057,354,970 | 1,639,514,970 | 1,480,680,000 |
| 租赁负债 | 298,171,401.32 | 322,123,514.3 | 480,087,220.34 | 494,538,627.12 |
| 预计负债 | 6,418,071 | 6,418,071 | - | - |
| 递延收益 | 141,759,054.48 | 144,575,186.69 | 141,346,468.6 | 144,513,152.4 |
| 递延所得税负债 | 17,569,231.29 | 17,621,910.41 | 17,817,871.75 | 17,218,120.35 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 2,448,092,689.21 | 2,548,093,652.4 | 2,278,766,530.69 | 2,136,949,899.87 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 9,148,712,017.42 | 9,042,959,631.29 | 8,441,565,786.49 | 8,501,486,397.07 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,365,251,515 | 1,365,251,515 | 1,365,251,515 | 1,365,251,515 |
| 资本公积 | 3,942,272,731.28 | 3,942,255,409.01 | 3,942,211,071.58 | 3,942,211,071.58 |
| 其他综合收益 | 9,846,472.3 | 51,058,725.86 | 54,994,069.08 | 10,282,726.62 |
| 盈余公积 | 466,773,396.09 | 466,773,396.09 | 466,773,396.09 | 466,773,396.09 |
| 一般风险准备 | 3,854,383.76 | 3,854,383.76 | 3,854,383.76 | 3,854,383.76 |
| 未分配利润 | 1,334,589,466.51 | 1,186,446,483.33 | 1,112,741,515.88 | 823,800,049.29 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 7,122,587,964.94 | 7,015,639,913.05 | 6,945,825,951.39 | 6,612,173,142.34 |
| 少数股东权益 | 1,527,235,336.97 | 1,503,912,726.78 | 1,534,586,667.04 | 1,538,860,375.83 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 8,649,823,301.91 | 8,519,552,639.83 | 8,480,412,618.43 | 8,151,033,518.17 |
| 负债和股东权益合计 | 17,798,535,319.33 | 17,562,512,271.12 | 16,921,978,404.92 | 16,652,519,915.24 |
| 公告日期 | 2025-04-30 | 2025-04-29 | 2024-10-29 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |